Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 2/2016

22.02.2016 | The Science of Prevention (JD Stekler and J Baeten, Section Editors)

Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings

verfasst von: Julia L. Marcus, Jonathan E. Volk, Jess Pinder, Albert Y. Liu, Oliver Bacon, C. Bradley Hare, Stephanie E. Cohen

Erschienen in: Current HIV/AIDS Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The past 3 years have marked a transition from research establishing the safety and efficacy of HIV preexposure prophylaxis (PrEP) to questions about how to optimize its implementation. Until recently, PrEP was primarily offered as part of randomized controlled trials or open-label studies. These studies highlighted the key components of PrEP delivery, including regular testing for HIV and other sexually transmitted infections (STIs), adherence and risk-reduction support, and monitoring for renal toxicity. PrEP is now increasingly provided in routine clinical settings. This review summarizes models for PrEP implementation from screening through initiation and follow-up, focusing on the strengths and weaknesses of three delivery systems: a health maintenance organization, an STI clinic, and a primary care practice. These early implementation experiences demonstrate that PrEP can be successfully delivered across a variety of settings and highlight strategies to streamline PrEP delivery in clinical practice.
Literatur
1.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRefPubMedPubMedCentral
2.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.CrossRefPubMed
3.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRefPubMedPubMedCentral
4.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRefPubMed
5.
6.•
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet. 2014;14:820–9. Uptake of PrEP was high in this open-label extension of randomized PrEP trials, particularly among individuals reporting condomless receptive anal intercourse. PrEP efficacy was highly correlated with drug concentrations in dried blood spots, and there were no HIV seroconversions in participants who had drug levels consistent with having taken four or more doses of TDF/FTC per week.CrossRefPubMed
7.•
Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP Demonstration Project. J Acquir Immune Defic Syndr. 2015;68:439–48. In this report of baseline data from an open-label demonstration project in STI clinics and a community health center in three US cities (The US Demonstration Project), uptake of PrEP was high in a diverse population of MSM at risk for HIV infection and did not vary by race/ethnicity, age, or education level.CrossRefPubMedPubMedCentral
8.
Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Liu N, et al. An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for young men who have sex with men in the United States (ATN 110). In: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver; 2015.
9.
Flash C, Landovitz R, Giler RM, Ng L, Magnuson D, Wooley SB, et al. Two years of Truvada for pre-exposure prophylaxis utilization in the US. J Int AIDS Soc. 2014;17:19730.CrossRefPubMedPubMedCentral
10.
Grant RM, Liu A, Hecht J, Buchbinder SP, Weber S, Crouch P, et al. Scale-up of preexposure prophylaxis in San Francisco to impact HIV incidence. In: 22nd Conference on Retroviruses and Opportunistic Infections. Seattle; 2015.
11.
Mayer K, Krakower D, Levine K, Grasso C, Gelman M. Significant increases in HIV pre-exposure prophylaxis (PrEP) uptake in Boston, a Boston Community Health Center in 2014: who are the recent users? In: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver; 2015.
12.
Hood J, Buskin S, Barash E, Katz D, Dombrowski J, Golden M. Awareness and utilization of HIV prevention innovations among men who have sex with men in Seattle. In: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver; 2015.
13.•
Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):1–11. In this report from the US Demonstration Project, adherence, as measured in dried blood spots, was higher than that observed in clinical trials of PrEP and was correlated with higher self-reported risk behaviors. HIV incidence was extremely low, despite a high incidence of STIs.
14.
Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2013;44:S91–8.CrossRefPubMed
15.
Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS. 2015;29:819–24.CrossRefPubMed
16.
Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.PubMedPubMedCentral
17.
Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;66:530–7.CrossRefPubMedPubMedCentral
18.
Agot K, Taylor D, Corneli AL, Wang M, Ambia J, Kashuba AD, et al. Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials. AIDS Behav. 2015;19:743–51.CrossRefPubMedPubMedCentral
19.
Mayer KH, Safren SA, Haberer J, Elsesser S, Clarke W, Hendrix CW, et al. Project PrEPARE: high levels of medication adherence with continued condomless sex in U.S. men who have sex with men in an oral PrEP adherence trial. AIDS Res Hum Retrovir. 2014;30:A23–4.CrossRef
20.
Liu A, Stojanovski K, Lester RT, Amico KR, McMahan V, Goicochea P, et al. Developing and implementing a mobile health (mHealth) adherence support system for HIV-uninfected men who have sex with men (MSM) taking pre-exposure prophylaxis (PrEP): the iText Study. In: 8th International Conference on HIV Treatment and Prevention. Miami; 2014.
21.
22.
Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis. 2015;211:1211–8.PubMed
23.
Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29:331–7.CrossRefPubMed
24.
Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210:1217–27.CrossRefPubMedPubMedCentral
25.
Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572–80.
26.
Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS ONE. 2011;6, e23688.CrossRefPubMedPubMedCentral
27.
Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Int Med. 2015;175:246–54.CrossRef
28.
Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851–9.CrossRefPubMedPubMedCentral
29.
Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8, e81997.CrossRefPubMedPubMedCentral
30.
Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13:1021–8.CrossRefPubMedPubMedCentral
31.
Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. Sexual risk behavior among HIV-uninfected men who have sex with men (MSM) participating in a tenofovir pre-exposure prophylaxis (PrEP) randomized trial in the United States. J Acquir Immune Defic Syndr. 2013;64(1):87-94.
32.
Elsesser S, Biello K, Taylor S, Tomassilli J, Safren SA, Mayer K. Absence of sexual behavioral disinhibition in a PrEP adherence trial: considerations for medical providers who prescribe PrEP for men who have sex with men (MSM). In: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver; 2015.
33.
Milam J, Jain S, Moore D, Daar E, Dube M, Young J, et al. Risk compensation among men who have sex with men (MSM) in Southern California following the initiation of pre-exposure prophylaxis (PrEP). In: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver; 2015.
34.
35.••
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53-60. In this pragmatic open-label trial in the UK, participants at 13 sexual health clinics were randomized to receive immediate or deferred PrEP. HIV incidence was high in the deferred arm, with an 86 % risk reduction in the immediate arm. There was no evidence of an increase in STI incidence.
36.•
Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3. This real-world evaluation of PrEP in a large clinical practice setting found No new HIV infections in a growing population of PrEP users, despite high STI incidence and a reported decrease in condom use in a subset of patients.
37.
Volk JE, Marcus JL, Phengrasamy T, Hare CB. Incident hepatitis C virus infections among users of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;60(11):1728–9.
38.
39.
40.
van der Helm JJ, Hoebe CJ, van Rooijen MS, Brouwers EE, Fennema HS, Thiesbrummel HF, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis. 2009;36:493–7.CrossRefPubMed
41.
Freeman AH, Bernstein KT, Kohn RP, Philip S, Rauch LM, Klausner JD. Evaluation of self-collected versus clinician-collected swabs for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae pharyngeal infection among men who have sex with men. Sex Transm Dis. 2011;38:1036–9.CrossRefPubMed
42.
43.
Klein D, Hurley LB, Merrill D, Quesenberry Jr CP. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr. 2003;32:143–52.CrossRefPubMed
44.
Nurutdinova D, Rao S, Shacham E, Reno H, Overton ET. STD/HIV risk among adults in the primary care setting: are we adequately addressing our patients’ needs? Sex Transm Dis. 2011;38:30–2.CrossRefPubMed
45.
Montano DE, Phillips WR, Kasprzyk D, Greek A. STD/HIV prevention practices among primary care clinicians: risk assessment, prevention counseling, and testing. Sex Transm Dis. 2008;35:154–66.CrossRefPubMed
46.
Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S122–9.CrossRefPubMedPubMedCentral
47.
Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11, e1001613.CrossRefPubMedPubMedCentral
48.
49.
Patel P, Klausner JD, Bacon OM, Liska S, Taylor M, Gonzalez A, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr. 2006;42:75–9.CrossRefPubMed
50.
Landovitz RJ, Combs KB, Currier JS. Availability of HIV postexposure prophylaxis services in Los Angeles County. Clin Infect Dis. 2009;48:1624–7.CrossRefPubMedPubMedCentral
51.
52.
Metadaten
Titel
Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings
verfasst von
Julia L. Marcus
Jonathan E. Volk
Jess Pinder
Albert Y. Liu
Oliver Bacon
C. Bradley Hare
Stephanie E. Cohen
Publikationsdatum
22.02.2016
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 2/2016
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-016-0308-x

Weitere Artikel der Ausgabe 2/2016

Current HIV/AIDS Reports 2/2016 Zur Ausgabe

The Science of Prevention (JD Stekler and J Baeten, Section Editors)

Cascade of Refusal—What Does It Mean for the Future of Treatment as Prevention in Sub-Saharan Africa?

The Science of Prevention (JD Stekler and J Baeten, Section Editors)

HIV Self-Testing: a Review of Current Implementation and Fidelity

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

NK Cells in HIV Disease

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

How to Define the Latent Reservoir: Tools of the Trade

The Science of Prevention (JD Stekler and J Baeten, Section Editors)

Current and (Potential) Future Effects of the Affordable Care Act on HIV Prevention

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise